Production (Stage)
Theravance Biopharma, Inc.
TBPH
$9.30
-$0.19-2.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.58M | -15.53M | -12.70M | -16.53M | -11.66M |
| Total Depreciation and Amortization | 1.38M | 1.48M | 1.56M | 1.91M | 1.53M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.30M | -737.00K | 6.29M | 7.51M | 4.99M |
| Change in Net Operating Assets | 51.94M | 13.89M | -342.00K | 2.69M | 4.12M |
| Cash from Operations | 43.04M | -902.00K | -5.20M | -4.42M | -1.02M |
| Capital Expenditure | -- | -190.00K | -15.00K | -36.00K | -91.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.63M | 15.88M | -17.38M | -3.00M | 17.12M |
| Cash from Investing | 30.63M | 15.69M | -17.40M | -3.03M | 17.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.00K | 163.00K | 25.00K | 419.00K | -- |
| Repurchase of Common Stock | -874.00K | -528.00K | -397.00K | -463.00K | -1.72M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -854.00K | -365.00K | -372.00K | -44.00K | -1.72M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.82M | 14.42M | -22.97M | -7.49M | 14.29M |